changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact email@example.com
Not all indications may be available in all territories.
DC BeadM1™ delivers more drug to the tumour with promising clinical outcomes and favourable safety.6,7
The gold-standard Drug-Eluting Bead, DC Bead™ is supported by ten years' experience and more than 100 publications in over 6,000 HCC patients.2
The benefits of DC Bead™ are supported by over 150 peer reviewed papers and are now recognised in the European Clinical Practice Guidelines for HCC4,5
DC Bead™ is challenging survival expectations for intermediate HCC patients2, 3
Launched in 2005 DC Bead is the leading drug eluting bead that has been used to treat patients requiring transarterial chemoembolisation (TACE) in malignant hypervascularised tumour(s) and malignant colorectal cancer metastasised in the liver
The gold-standard Drug-Eluting Bead, DC Bead™ is supported by ten years' experience and more than 80 publications reporting outcomes in over 3000 HCC patients.2
GEST ASIA 2018
BOSTON SCIENTIFIC CLOSES ACQUISITION OF ...
BTG plc acquires Novate Medical Ltd.
BTG plc acquires Roxwood Medical
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com